{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:08:48Z","timestamp":1790114928699,"version":"4.0.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jpba.2026.117686","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T16:03:24Z","timestamp":1785341004000},"page":"117686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A fast method for the quantification of bortezomib in serum and rat nervous tissue by liquid chromatography tandem mass spectrometry"],"prefix":"10.1016","volume":"281","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4275-8774","authenticated-orcid":false,"given":"Jonas Moritz","family":"Huhn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4746-6778","authenticated-orcid":false,"given":"Mona","family":"Hashemian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6381-8991","authenticated-orcid":false,"given":"Martina","family":"Kinzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabete","family":"B\u00f3f Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz","family":"S\u00f6rgel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1967-9231","authenticated-orcid":false,"given":"Oliver","family":"Scherf-Clavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2026.117686_bib1","first-page":"146","article-title":"Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications","volume":"22","author":"Alwahsh","year":"2023","journal-title":"EXCLI J."},{"key":"10.1016\/j.jpba.2026.117686_bib2","first-page":"471","article-title":"Advances in the understanding of mechanisms and therapeutic use of bortezomib","volume":"12","author":"Mujtaba","year":"2011","journal-title":"Discov. Med."},{"key":"10.1016\/j.jpba.2026.117686_bib3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/107327480301000502","article-title":"Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers","volume":"10","author":"Richardson","year":"2003","journal-title":"Cancer Control."},{"key":"10.1016\/j.jpba.2026.117686_bib4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","article-title":"The development of proteasome inhibitors as anticancer drugs","volume":"5","author":"Adams","year":"2004","journal-title":"Cancer Cell."},{"key":"10.1016\/j.jpba.2026.117686_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.123125","article-title":"Bortezomib in cancer therapy: Mechanisms, side effects, and future proteasome inhibitors","volume":"358","author":"Sogbein","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.jpba.2026.117686_bib6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jpba.2008.09.053","article-title":"Elucidation of potential bortezomib response markers in mutliple myeloma patients","volume":"49","author":"Hsieh","year":"2009","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117686_bib7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10928-019-09670-3","article-title":"Population-based meta-analysis of bortezomib exposure-response relationships in multiple myeloma patients","volume":"47","author":"Zhang","year":"2020","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.jpba.2026.117686_bib8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40262-018-0679-9","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib","volume":"58","author":"Tan","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2026.117686_bib9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00280-010-1283-3","article-title":"Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma","volume":"67","author":"Reece","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jpba.2026.117686_bib10","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1158\/1078-0432.CCR-11-2873","article-title":"Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432","volume":"18","author":"LoRusso","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jpba.2026.117686_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jchromb.2013.01.037","article-title":"Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC\/MS\/MS","volume":"926","author":"Andriamanana","year":"2013","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2026.117686_bib12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7324\/JAPS.2017.70105","article-title":"A Validated LC-MS\/MS Method for the Estimation of Bortezomib and Bortezomib D3 (IS) in Human Plasma with Protein Precipitation and SPE Filter Cartridges","author":"Chandramowli","year":"2017","journal-title":"J. Appl. Pharm. Sci."},{"key":"10.1016\/j.jpba.2026.117686_bib13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jchromb.2016.06.009","article-title":"LC-MS\/MS method for simultaneous determination of thalidomide, lenalidomide, cyclophosphamide, bortezomib, dexamethasone and adriamycin in serum of multiple myeloma patients","volume":"1028","author":"Shu","year":"2016","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2026.117686_bib14","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1080\/17435889.2024.2382668","article-title":"Simultaneous estimation of paclitaxel and bortezomib via LC-MS\/MS: pharmaceutical and pharmacokinetic applications","volume":"19","author":"Yadav","year":"2024","journal-title":"Nanomed. (Lond. )"},{"key":"10.1016\/j.jpba.2026.117686_bib15","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1124\/dmd.104.002956","article-title":"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites","volume":"33","author":"Pekol","year":"2005","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.jpba.2026.117686_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2026.117389","article-title":"Development and validation of an UPLC-MS\/MS method for simultaneous determination of meropenem and its open-ring metabolite in human serum and cerebrospinal fluid with application to clinical samples","volume":"273","author":"Chen","year":"2026","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117686_bib17","unstructured":"International Council of Harmonization of Technical Requirements for Pharmaceuticals for Human Use, ICH guideline M10 on bioanalytical method validation. https:\/\/www.ema.europa.eu\/en\/ich-m10-bioanalytical-method-validation-scientific-guideline, 2022 (accessed 19 January 2026)."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526003547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526003547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:45:55Z","timestamp":1790113555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708526003547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":17,"alternative-id":["S0731708526003547"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117686","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A fast method for the quantification of bortezomib in serum and rat nervous tissue by liquid chromatography tandem mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117686","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117686"}}